News | September 22, 2009

Robotic Stereotactic Radiotherapy Safe Alternative to Fractionated Radiotherapy

September 22, 2009 - Robotic stereotactic radiotherapy appeared to be a safe and obviously superior alternative to conventionally fractionated radiotherapy in a small cohort of patients with stage I non-small cell lung cancer (NSCLC), according to a study published in the October issue of Clinical Oncology.

In the study, researchers set out to determine the effectiveness of robotic stereotactic radiotherapy with image guidance and real-time respiratory tracking against early stage peripheral lung cancer.

All patients with stage I non-small cell lung cancer (NSCLC) were treated using CyberKnife. All patients had co-morbid conditions that precluded lobectomy. The clinical target volume (CTV) included the gross tumour volume (GTV) and a 6 mm margin in all directions to account for microscopic extension. The planning target volume (PTV) equalled CTVD + 2 mm in all directions for uncertainty. Tumor motion was tracked using a combination of Synchrony and Xsight Spine tracking methods with the aid of a single gold marker implanted in the center of the tumor, or using the newer Xsight Lung method without markers for selected tumors. A 60-67.5 Gy dose was prescribed to the 60-80 percent isodose line (median 65 percent) and given in three to five fractions. Patients were followed every 3 months for a median of 27.5 months (range 24-53 months).

Of the 67 patients with NSCLC stage IA or IB treated between January 2004 and December 2008, investigators reported the results of a cohort of 31 with peripheral stage I tumors of 0.6-71 cm3 volume treated between January 2004 and December 2007 with total doses between 60 and 67.5 Gy in three to five fractions. The median Dmax was 88.2 Gy and the median V95 of the PTV was 99.6 percent or 27.9 cm3. No grade 3 or above toxicity was encountered. Four cases of radiation pneumonitis and one case of oesophagitis were observed. In those patients whose pre- and post-treatment results were available, no change in pulmonary function tests was observed. Actuarial local control was 93.2 percent for 1 year and 85.8 percent for up to 4.5 years. One-year overall survival was 93.6 percent and 83.5 percent for up to 4.5 years, as projected by Kaplan-Meier analyses.

The researchers concluded that in this small cohort of patients with stage I peripheral NSCLC, robotic stereotactic radiotherapy seems to be a safe and obviously superior alternative to conventionally fractionated radiotherapy, with results that may be approaching those obtained with lobectomy without the associated morbidity.

Reference: Brown, W.T., Wu, X., Fayad, F., Fowler, J.F., García, S., Monterroso, M.I., de la Zerda, A., Schwade, J.G. Application of Robotic Stereotactic Radiotherapy to Peripheral Stage I Non-Small Cell Lung Cancer With Curative Intent. Clin Oncol. 2009 Oct 1;21(8):623-631.

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
Overlay Init